300966.SHE Hubei Goto Biopharm Co.Ltd.
- Market cap
- CNY 2.76B
- P/E
- -
- P/B
- 3.56x
- ROE
- -8.4%
- Dividend yield
- 1.08%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300966.SHE undervalued?
Graham numberThe Graham number of Hubei Goto Biopharm Co.Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hubei Goto Biopharm Co.Ltd. fundamental analysis
No fundamental analysis for Hubei Goto Biopharm Co.Ltd. yet.
Hubei Goto Biopharm Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other materials. The company was formerly known as Hubei Goto Biopharm Co.,Ltd. and changed its name to Hubei Goto Biopharm Group Co., Ltd. in June 2026. Hubei Goto Biopharm Group Co., Ltd. was founded in 2006 and is based in Xiangyang, China.
Full company profileHubei Goto Biopharm Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hubei Goto Biopharm Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 334M | 437M | 465M | 468M | 591M | 605M | 566M | 537M | 606M | 686M |
| Gross Profit | 102M | 128M | 129M | 106M | 144M | 138M | 116M | 101M | 83.5M | 101M |
| Operating Income | 55.2M | 78.3M | 79.7M | 57.3M | 62.7M | 38.9M | 19.5M | -42.4M | -33.6M | -21.3M |
| EBITDA | 84.5M | 120M | 123M | 88.7M | 115M | 77.4M | 59.1M | 22.2M | 57.9M | -31.9M |
| Net Income | 47.4M | 70.7M | 73.0M | 53.3M | 78.3M | 40.2M | 23.0M | -27.6M | -73.4M | -65.0M |
| EPS | 1.03 | 0.84 | 0.85 | 0.62 | 0.74 | 0.35 | 0.20 | -0.24 | -0.64 | -0.56 |
| Balance Sheet | ||||||||||
| Total Assets | 483M | 615M | 818M | 804M | 1.21B | 2.07B | 2.45B | 2.79B | 2.85B | 2.95B |
| Total Liabilities | 183M | 207M | 336M | 265M | 383M | 1.09B | 1.42B | 1.78B | 1.94B | 2.10B |
| Shareholders' Equity | 300M | 408M | 481M | 535M | 807M | 928M | 953M | 923M | 826M | 776M |
| Cash & Short-term Investments | 44.1M | 65.1M | 130M | 29.0M | 210M | 453M | 182M | 141M | 85.8M | 108M |
| Total Debt | 56.0M | 80.9M | 147M | 140M | 162M | 770M | 763M | 1.11B | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -22.1M | -47.9M | 8.50M | 13.5M | 58.0M | -24.0M | 68.1M | -20.6M | 41.0M | - |
| Capital Expenditure | 19.7M | 13.9M | 33.3M | 18.6M | 90.9M | 408M | 409M | 312M | 166M | 107M |
| Free Cash Flow | -41.7M | -61.8M | -24.8M | -5.09M | -32.9M | -432M | -341M | -332M | -125M | -44.8M |
| Ratios | ||||||||||
| ROE | 15.8% | 17.3% | 15.2% | 10.0% | 9.7% | 4.3% | 2.4% | -3.0% | -8.9% | -8.4% |
| ROA | 9.8% | 11.5% | 8.9% | 6.6% | 6.5% | 1.9% | 0.9% | -1.0% | -2.6% | -2.2% |
| Net Profit Margin | 14.2% | 16.2% | 15.7% | 11.4% | 13.3% | 6.7% | 4.1% | -5.1% | -12.1% | -9.5% |
| Debt to Equity | 0.19x | 0.20x | 0.31x | 0.26x | 0.20x | 0.83x | 0.80x | 1.20x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hubei Goto Biopharm Co.Ltd. dividends
- Dividend yield
- 1.08%
- Forward dividend
- 0.05 CNY
- Payout ratio
- -
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 29.8M | 0.26 | - |
| 2024 | CNY 25.7M | 0.22 | - |
| 2023 | CNY 6.09M | 0.05 | 26.5% |
| 2022 | CNY 15.7M | 0.14 | 39.0% |
| 2021 | CNY 7.58M | 0.07 | 9.7% |
| 2020 | CNY 9.16M | 0.11 | 17.2% |
| 2019 | CNY 9.26M | 0.11 | 12.7% |
| 2018 | 4.62M | 0.05 | 6.5% |
| 2017 | 3.31M | 0.07 | 7.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hubei Goto Biopharm Co.Ltd.
- Insiders 49.14%
- Institutions 3.96%
- Public & others 46.90%
- Shares outstanding 115M
- Free float 60.3M
Hubei Goto Biopharm Co.Ltd. company profile
- Company name
- Hubei Goto Biopharm Co.Ltd.
- Ticker
- 300966.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 893
- Fiscal year end
- December
- Address
- Building 1, Global Financial City, Xiangyang, China, 441057
- Phone
- 86 71 0342 3122
- Website
- gotopharm.com
About Hubei Goto Biopharm Co.Ltd.
Hubei Goto Biopharm Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other materials. The company was formerly known as Hubei Goto Biopharm Co.,Ltd. and changed its name to Hubei Goto Biopharm Group Co., Ltd. in June 2026. Hubei Goto Biopharm Group Co., Ltd. was founded in 2006 and is based in Xiangyang, China.
Hubei Goto Biopharm Co.Ltd. management
4- Mr. Zubin XiChairman of the Board, GM and Research & Development Director · born 1970
- Mr. Xiangdong LiuCFO, Head of Accounting Agency & Non-Independent Director · born 1974
- Mr. Minglei LiNon Independent Director & Deputy GM · born 1977
- Ms. Wenjing ChenBoard Secretary & Deputy GM · born 1973